SEFRIA Oxycodone Oral Fluid Enzyme Immunoassay
Device Facts
| Record ID | K203564 |
|---|---|
| Device Name | SEFRIA Oxycodone Oral Fluid Enzyme Immunoassay |
| Applicant | Immunalysis Corporation |
| Product Code | DJG · Clinical Toxicology |
| Decision Date | Dec 22, 2021 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.3650 |
| Device Class | Class 2 |
Indications for Use
The Immunalysis SEFRIA Oxycodone Oral Fluid Enzyme Immunoassay is a homogeneous enzyme immunoassay with a cutoff of 30 ng/mL in neat oral fluid collected by Quantisal or Quantisal II Oral Fluid Collection Device. The assay is intended for the qualitative and semi-quantitative analysis of oxycodone in human oral fluid with clinical analyzers. This assay is calibrated against oxycodone. The semi-quantitative mode is for purposes of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Gas Chromatography/Mass Spectrometry (GC-MS) or Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) or permitting laboratories to establish quality control procedures. The Immunalysis SEFRIA Oxycodone Oral Fluid Enzyme Immunoassay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC-MS) or Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any test result, particularly when preliminary positive results are used.
Device Story
Homogeneous enzyme immunoassay for oxycodone detection in human oral fluid; utilizes Quantisal/Quantisal II collection devices. Principle: competitive binding between sample oxycodone and ED-oxycodone conjugate for antibody sites; inhibits enzyme complementation of β-galactosidase fragments. Enzyme activity measured spectrophotometrically at 570 nm via CPRG substrate conversion. Used in clinical laboratories on automated chemistry analyzers (e.g., Beckman Coulter AU480). Provides preliminary results; requires confirmation via GC-MS or LC-MS/MS. Enables semi-quantitative dilution determination for confirmatory testing and quality control. Benefits: rapid screening for oxycodone presence to guide clinical decision-making.
Clinical Evidence
Bench testing only. Precision/reproducibility studies (N=60 per concentration) across 15-20 days confirmed repeatability. Linearity demonstrated 10-100 ng/mL range. Method comparison study using 80 clinical oral fluid samples showed 100% agreement with LC-MS/MS reference method in both qualitative and semi-quantitative modes. Interference testing confirmed no cross-reactivity with structurally related/unrelated compounds or endogenous/exogenous substances at tested concentrations.
Technological Characteristics
Homogeneous enzyme immunoassay; reagents include Enzyme Acceptor (EA) with recombinant antibodies and Enzyme Donor (ED) labeled with oxycodone. Buffer: PIPES/malic acid with sodium azide preservative. Detection: spectrophotometric (570 nm). Form factor: liquid reagents for automated clinical chemistry analyzers. Storage: 2-8°C.
Indications for Use
Indicated for the qualitative and semi-quantitative analysis of oxycodone in human oral fluid collected via Quantisal or Quantisal II devices. For in vitro diagnostic use in clinical laboratories. Prescription use only.
Regulatory Classification
Identification
An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.
Special Controls
*Classification.* Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
Predicate Devices
- Thermo Scientific CEDIA Opiate OFT Assay (K101754)
Related Devices
- K252520 — SEFRIA Hydrocodone Oral Fluid · Immunalysis Corporation · Sep 11, 2025
- K024339 — COZART EIA OPIATES ORAL FLUID KIT · Cozart Bioscience , Ltd. · Apr 7, 2003
- K051626 — IMMUNALYSIS OPIATES ELISA FOR ORAL FLUIDS · Immunalysis Corporation · Oct 13, 2005
- K131168 — IMMUNALYSIS OXYCODONE ENZYME IMMUNOASSAY · Immunalysis Corporation · Jan 17, 2014
Submission Summary (Full Text)
{0}
FDA U.S. FOOD & DRUG ADMINISTRATION
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
ASSAY ONLY
## I Background Information:
A 510(k) Number
K203564
B Applicant
Immunalysis Corporation
C Proprietary and Established Names
SEFRIA™ Oxycodone Oral Fluid Enzyme Immunoassay
D Regulatory Information
| Product Code(s) | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| DJG | Class II | 21 CFR 862.3650 - Opiate Test System | TX - Clinical Toxicology |
## II Submission/Device Overview:
A Purpose for Submission:
New Device
B Measurand:
Oxycodone
C Type of Test:
Qualitative and Semi-quantitative Homogeneous Enzyme Immunoassay
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov
{1}
K203564 - Page 2 of 18
## III Intended Use/Indications for Use:
### A Intended Use(s):
See Indications for Use below.
### B Indication(s) for Use:
For In Vitro Diagnostic Use.
The Immunalysis SEFRIA Oxycodone Oral Fluid Enzyme Immunoassay is a homogeneous enzyme immunoassay with a cutoff of 30 ng/mL in neat oral fluid collected by Quantisal or Quantisal II Oral Fluid Collection Device. The assay is intended for the qualitative and semi-quantitative analysis of oxycodone in human oral fluid with clinical analyzers. This assay is calibrated against oxycodone.
The semi-quantitative mode is for purposes of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Gas Chromatography/Mass Spectrometry (GC-MS) or Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) or permitting laboratories to establish quality control procedures.
The Immunalysis SEFRIA Oxycodone Oral Fluid Enzyme Immunoassay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC-MS) or Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any test result, particularly when preliminary positive results are used.
### C Special Conditions for Use Statement(s):
Rx - For Prescription Use Only
### D Special Instrument Requirements:
The SEFRIA™ Oxycodone Oral Fluid Enzyme Immunoassay was validated using the Beckman Coulter AU480 chemistry analyzer. Confirmatory tests were run in the Agilent 6430 Liquid Chromatography-Tandem Mass Spectrometry.
## IV Device/System Characteristics:
### A Device Description:
The SEFRIA Oxycodone Oral Fluid Enzyme Immunoassay consists of ready to use reagents for use on automated clinical chemistry analyzers. The SEFRIA Oxycodone Oral Fluid Enzyme Immunoassay is provided in two kit sizes by volume: 100 mL (621OF-0100K) and 500 mL (621OF-0500K). Each kit box contains the following reagents:
- 1 X Enzyme Acceptor/Antibody Reagent (EA) - This contains EA protein and recombinant antibodies to oxycodone, in PIPES buffer with sodium azide as a preservative.
{2}
- 1 X Enzyme Donor/Substrate Reagent (ED) - This contains ED peptide labeled with oxycodone and CPRG substrate in malic acid buffer with sodium azide as a preservative.
## B Principle of Operation:
The SEFRIA technology is based on artificial fragments of the E. coli enzyme β-galactosidase. A mutant enzyme, termed Enzyme Acceptor (EA), is created by deletion of a short sequence in the amino-terminal region of the sequence. EA is inactive, but can combine with peptides, termed Enzyme Donors (ED's), containing the deleted sequence, to form active β-galactosidase. This process is termed complementation, and the active enzyme formed as a result can be measured by hydrolysis of a chromogenic substrate such as chlorophenol red β-D-galactopyranoside (CPRG). The ED peptides can be modified by attachment of a derivative of oxycodone, which does not interfere with the formation of active β-galactosidase. However, antibodies to oxycodone bind to the ED-oxycodone conjugate, and block complementation. The assay is based on the competition of oxycodone in an oral fluid sample with the ED-oxycodone conjugate for the fixed amount of antibody binding sites. In the absence of the free drug in the sample, the antibody binds the ED-oxycodone conjugate, resulting in inhibition of enzyme formation. As the oxycodone concentration in the sample increases, ED-oxycodone becomes available for complementation, creating a dose response relationship between oxycodone concentration in the oral fluid and enzyme formation. The β-galactosidase activity is determined spectrophotometrically at 570 nm by the conversion of CPRG (orange) to chlorophenol red (red) and galactose.
## V Substantial Equivalence Information:
## A Predicate Device Name(s):
Thermo Scientific CEDIA Opiate OFT Assay
## B Predicate 510(k) Number(s):
K101754
## C Comparison with Predicate(s):
| Device & Predicate Device(s): | K203564 | K101754 |
| --- | --- | --- |
| Device Trade Name | SEFRIA™ Oxycodone Oral Fluid Enzyme Immunoassay | Thermo Scientific CEDIA Opiate OFT Assay |
| General Device Characteristic Similarities | | |
| Intended Use/Indications For Use | Qualitative determination of opiates in human oral fluid | Same |
| Test Principle | Homogeneous enzyme immunoassay | Same |
| Assay Materials | Antibody reagent, drug conjugate reagent | Same |
K203564 - Page 3 of 18
{3}
| Device & Predicate Device(s): | K203564 | K101754 |
| --- | --- | --- |
| Cutoff Level | 30 ng/mL in Neat Oral Fluid | Same |
| User Environment | For use in laboratories | Same |
| Sample Matrix | Human oral fluid | Same |
| Reagent Storage | 2-8°C until expiration date | Same |
| Mass Spectrometry Confirmation | Required for preliminary positive analytical results | Same |
| General Device Characteristic Differences | | |
| Calibrated Against | Oxycodone | Morphine |
| Sample Collection Device | Oral fluid collected with the Quantisal and Quantisal II Oral Fluid Collection Devices. | Oral fluid is collected with the Oral Eze™ Saliva Collection System. |
VI Standards/Guidance Documents Referenced:
CLSI EP07-A2: Interference Testing in Clinical Chemistry; Approved Guideline – Second Edition
ISO 14971:2007 Medical Devices – Application of Risk Management to Medical Devices
EN ISO 14971:2012 Medical Devices – Application of Risk Management to Medical Devices
VII Performance Characteristics (if/when applicable):
A Analytical Performance:
1. Precision/Reproducibility:
Precision study was performed over 15 days, 2 runs per day with 2 collection devices per run (N=60), one replicate per collection device on 1 lot of reagent and 1 lot of Quantisal and 1 lot of Quantisal II oral fluid collection devices. Drug free negative oral fluid was spiked to concentrations of assay cutoff and ±25%, ±50%, ±75%, ±100% of the cutoff and was collected using the collection devices. The spiked concentrations were confirmed by liquid chromatography tandem mass spectrometry (LC-MS/MS) before collection. The study established the repeatability of the testing system, including assay and oral fluid collection device. Test results in qualitative and semi-quantitative modes are presented in the following tables.
K203564 - Page 4 of 18
{4}
Precision – Qualitative results from samples collected using Quantisal
| Concentration (ng/mL) | % of Cutoff | # of Determinations | Result |
| --- | --- | --- | --- |
| 0 | -100% | 60 | 60 Negative |
| 7.5 | -75% | 60 | 60 Negative |
| 15 | -50% | 60 | 60 Negative |
| 22.5 | -25% | 60 | 60 Negative |
| 30 | Cutoff | 60 | 31 Neg/29 Pos |
| 37.5 | +25% | 60 | 60 Positive |
| 45 | +50% | 60 | 60 Positive |
| 52.5 | +75% | 60 | 60 Positive |
| 60 | +100% | 60 | 60 Positive |
Precision - Semi-Quantitative results from samples collected using Quantisal
| Concentration (ng/mL) | % of Cutoff | # of Determinations | Mean Conc. (ng/mL) | Result |
| --- | --- | --- | --- | --- |
| 0 | -100% | 60 | -0.2 | 60 Negative |
| 7.5 | -75% | 60 | 8.4 | 60 Negative |
| 15 | -50% | 60 | 16.7 | 60 Negative |
| 22.5 | -25% | 60 | 24.3 | 60 Negative |
| 30 | Cutoff | 60 | 32.3 | 16 Neg/44 Pos |
| 37.5 | +25% | 60 | 42.1 | 60 Positive |
| 45 | +50% | 60 | 53.3 | 60 Positive |
| 52.5 | +75% | 60 | 64.3 | 60 Positive |
| 60 | +100% | 60 | 76.3 | 60 Positive |
Precision – Qualitative results from samples collected using Quantisal II Pad A
| Concentration (ng/mL) | % of Cutoff | # of Determinations | Result |
| --- | --- | --- | --- |
| 0 | -100% | 60 | 60 Negative |
| 7.5 | -75% | 60 | 60 Negative |
| 15 | -50% | 60 | 60 Negative |
| 22.5 | -25% | 60 | 60 Negative |
| 30 | Cutoff | 60 | 31 Neg/29 Pos |
| 37.5 | +25% | 60 | 60 Positive |
| 45 | +50% | 60 | 60 Positive |
| 52.5 | +75% | 60 | 60 Positive |
| 60 | +100% | 60 | 60 Positive |
K203564 - Page 5 of 18
{5}
Precision - Semi-Quantitative results from samples collected using Quantisal II Pad A
| Concentration (ng/mL) | % of Cutoff | # of Determinations | Result |
| --- | --- | --- | --- |
| 0 | -100% | 60 | 60 Negative |
| 7.5 | -75% | 60 | 60 Negative |
| 15 | -50% | 60 | 60 Negative |
| 22.5 | -25% | 60 | 60 Negative |
| 30 | Cutoff | 60 | 36 Neg/24 Pos |
| 37.5 | +25% | 60 | 60 Positive |
| 45 | +50% | 60 | 60 Positive |
| 52.5 | +75% | 60 | 60 Positive |
| 60 | +100% | 60 | 60 Positive |
Precision - Qualitative results from samples collected using Quantisal II Pad B
| Concentration (ng/mL) | % of Cutoff | # of Determinations | Result |
| --- | --- | --- | --- |
| 0 | -100% | 60 | 60 Negative |
| 7.5 | -75% | 60 | 60 Negative |
| 15 | -50% | 60 | 60 Negative |
| 22.5 | -25% | 60 | 60 Negative |
| 30 | Cutoff | 60 | 28 Neg/32 Pos |
| 37.5 | +25% | 60 | 60 Positive |
| 45 | +50% | 60 | 60 Positive |
| 52.5 | +75% | 60 | 60 Positive |
| 60 | +100% | 60 | 60 Positive |
K203564 - Page 6 of 18
{6}
Precision - Semi-Quantitative results from samples collected using Quantisal II Pad B
| Concentration (ng/mL) | % of Cutoff | # of Determinations | Result |
| --- | --- | --- | --- |
| 0 | -100% | 60 | 60 Negative |
| 7.5 | -75% | 60 | 60 Negative |
| 15 | -50% | 60 | 60 Negative |
| 22.5 | -25% | 60 | 60 Negative |
| 30 | Cutoff | 60 | 28 Neg/32 Pos |
| 37.5 | +25% | 60 | 60 Positive |
| 45 | +50% | 60 | 60 Positive |
| 52.5 | +75% | 60 | 60 Positive |
| 60 | +100% | 60 | 60 Positive |
An additional 20-day study was performed on 3 lots of assay reagent to demonstrate the repeatability across multiple reagent lots. All sample concentrations ranging from $-100\%$ to $-25\%$ of the cutoff were negative and all sample concentrations ranging from $+25\%$ to $+100\%$ of cutoff were positive for both qualitative and semi-quantitative interpretations.
# 2. Linearity:
Assay linearity was evaluated in the semi-quantitative mode by spiking a drug free oral fluid pool with a high concentration of oxycodone. Additional pools were made by serially diluting the high concentration specimen with drug free oral fluid to achieve concentrations ranging from $10\mathrm{ng / mL}$ to $110\mathrm{ng / mL}$ . The $0\mathrm{ng / mL}$ specimen was made from drug free oral fluid. Each pool was collected by Quantisal and Quantisal II oral fluid collection devices and tested in triplicate to calculate the mean concentration values that were used to calculate drug recovery. The results in semi-quantitative mode are presented in the following tables.
Linearity/Recovery - Quantisal
| Expected Concentration (ng/mL) | Mean Concentration (ng/mL) | Recovery (%) |
| --- | --- | --- |
| 0 | 1.8 | N/A |
| 10 | 9.6 | 95.7 |
| 20 | 21.0 | 104.8 |
| 30 | 33.2 | 110.6 |
| 40 | 40.7 | 101.8 |
| 50 | 55.8 | 111.6 |
| 60 | 60.5 | 100.8 |
| 70 | 75.8 | 108.2 |
| 80 | 80.9 | 101.2 |
| 90 | 95.6 | 106.2 |
| 100 | 106.7 | 106.7 |
| 110 | 112.4 | 102.2 |
K203564 - Page 7 of 18
{7}
Linearity/Recovery – Quantisal II “Pad A”
| Expected Concentration (ng/mL) | Mean Concentration (ng/mL) | Recovery (%) |
| --- | --- | --- |
| 0 | -1.5 | N/A |
| 10 | 10.2 | 102.0 |
| 20 | 20.4 | 102.2 |
| 30 | 29.8 | 99.2 |
| 40 | 42.0 | 104.9 |
| 50 | 50.2 | 100.3 |
| 60 | 57.1 | 95.2 |
| 70 | 69.4 | 99.1 |
| 80 | 81.9 | 102.3 |
| 90 | 87.9 | 97.7 |
| 100 | 107.7 | 107.7 |
| 110 | 109.7 | 99.7 |
Linearity/Recovery – Quantisal II “Pad B”
| Expected Concentration (ng/mL) | Mean Concentration (ng/mL) | Recovery (%) |
| --- | --- | --- |
| 0 | -1.2 | N/A |
| 10 | 10.9 | 108.7 |
| 20 | 19.4 | 97.0 |
| 30 | 27.2 | 90.6 |
| 40 | 43.0 | 107.5 |
| 50 | 46.7 | 93.5 |
| 60 | 59.9 | 99.8 |
| 70 | 74.3 | 106.2 |
| 80 | 85.4 | 106.8 |
| 90 | 90.8 | 100.9 |
| 100 | 105.4 | 105.4 |
| 110 | 117.7 | 107.0 |
The study demonstrated that the SEFRIA™ Oxycodone Oral Fluid Enzyme Immunoassay has good correlation to the expected concentration in the range from 10 to 100 ng/mL.
3. Analytical Specificity/Interference:
Structurally and functionally similar compounds were spiked into drug free pooled oral fluid at levels that will yield a result that is equivalent to the cutoff, if cross reacting. The study assessed the cross reactivity of the oxycodone assay to related drugs and drug metabolites, in both the qualitative and semiquantitative modes. Cross-reactivity test results in qualitative and semi-quantitative modes are presented in the tables below.
K203564 - Page 8 of 18
{8}
Cross-Reactivity – Qualitative
| Compound | Compound Conc. (ng/mL) | Oxycodone Equivalent Conc. (ng/mL) | Result | Cross-Reactivity (%) |
| --- | --- | --- | --- | --- |
| 6-acetylcodeine | 40,000 | <30 | NEG | <0.08 |
| 6-acetylmorphine | 40,000 | <30 | NEG | <0.08 |
| Buprenorphine | 40,000 | <30 | NEG | <0.08 |
| Codeine | 40,000 | <30 | NEG | <0.08 |
| Desomorphine | 40,000 | <30 | NEG | <0.08 |
| Dihydrocodeine | 40,000 | <30 | NEG | <0.08 |
| Ethylmorphine | 40,000 | <30 | NEG | <0.08 |
| Fentanyl | 40,000 | <30 | NEG | <0.08 |
| Heroin | 40,000 | <30 | NEG | <0.08 |
| Hydrocodone | 40,000 | <30 | NEG | <0.08 |
| Hydromorphone | 40,000 | <30 | NEG | <0.08 |
| Levorphanol | 40,000 | <30 | NEG | <0.08 |
| Meperidine | 40,000 | <30 | NEG | <0.08 |
| Morphine | 40,000 | <30 | NEG | <0.08 |
| Morphine-3-β-D-glucuronide | 40,000 | <30 | NEG | <0.08 |
| Morphine-6-β-D-glucuronide | 40,000 | <30 | NEG | <0.08 |
| Naloxone | 6,000 | 30 | POS | 0.5 |
| Naltrexone | 40,000 | <30 | NEG | <0.08 |
| Norbuprenorphine | 40,000 | <30 | NEG | <0.08 |
| Norcodeine | 40,000 | <30 | NEG | <0.08 |
| Normorphine | 40,000 | <30 | NEG | <0.08 |
| Noroxycodone | 4,750 | 30 | POS | 0.6 |
| Noroxymorphone | 12,500 | 30 | POS | 0.2 |
| Oxymorphone | 35 | 30 | POS | 85.7 |
| Oxymorphone-3-β-D-glucuronide | 550 | 30 | POS | 5.5 |
| Tapentadol | 40,000 | <30 | NEG | <0.08 |
| Tramadol | 40,000 | <30 | NEG | <0.08 |
Cross-Reactivity – Semi-Quantitative
| Compound | Compound Conc. (ng/mL) | Oxycodone Equivalent Conc. (ng/mL) | Mean Value (ng/mL) | Result | Cross-Reactivity (%) |
| --- | --- | --- | --- | --- | --- |
| 6-acetylcodeine | 40,000 | <30 | 3.1 | NEG | <0.08 |
| 6-acetylmorphine | 40,000 | <30 | 2.1 | NEG | <0.08 |
| Buprenorphine | 40,000 | <30 | 1.4 | NEG | <0.08 |
| Codeine | 40,000 | <30 | 3.1 | NEG | <0.08 |
| Desomorphine | 40,000 | <30 | 3.2 | NEG | <0.08 |
| Dihydrocodeine | 40,000 | <30 | 4.0 | NEG | <0.08 |
| Ethylmorphine | 40,000 | <30 | 4.9 | NEG | <0.08 |
| Fentanyl | 40,000 | <30 | 2.1 | NEG | <0.08 |
K203564 - Page 9 of 18
{9}
| Compound | Compound Conc. (ng/mL) | Oxycodone Equivalent Conc. (ng/mL) | Mean Value (ng/mL) | Result | Cross-Reactivity (%) |
| --- | --- | --- | --- | --- | --- |
| Heroin | 40,000 | <30 | 1.9 | NEG | <0.08 |
| Hydrocodone | 40,000 | <30 | 4.7 | NEG | <0.08 |
| Hydromorphone | 40,000 | <30 | 4.1 | NEG | <0.08 |
| Levorphanol | 40,000 | <30 | 2.9 | NEG | <0.08 |
| Meperidine | 40,000 | <30 | 1.8 | NEG | <0.08 |
| Morphine | 40,000 | <30 | 4.0 | NEG | <0.08 |
| Morphine-3-β-D-glucuronide | 40,000 | <30 | 1.3 | NEG | <0.08 |
| Morphine-6-β-D-glucuronide | 40,000 | <30 | 1.2 | NEG | <0.08 |
| Naloxone | 6,000 | 30 | 32.5 | POS | 0.5 |
| Naltrexone | 40,000 | <30 | 19.8 | NEG | <0.08 |
| Norbuprenorphine | 40,000 | <30 | 1.3 | NEG | <0.08 |
| Norcodeine | 40,000 | <30 | 1.4 | NEG | <0.08 |
| Normorphine | 40,000 | <30 | 1.4 | NEG | <0.08 |
| Noroxycodone | 4,750 | 30 | 32.6 | POS | 0.6 |
| Noroxymorphone | 12,500 | 30 | 33.0 | POS | 0.2 |
| Oxymorphone | 35 | 30 | 31.0 | POS | 85.7 |
| Oxymorphone-3-β-D-glucuronide | 550 | 30 | 30.3 | POS | 5.5 |
| Tapentadol | 40,000 | <30 | 1.6 | NEG | <0.08 |
| Tramadol | 40,000 | <30 | 1.8 | NEG | <0.08 |
## Interference – Structurally Unrelated Compounds
Structurally unrelated compounds were evaluated in qualitative and semi-quantitative modes by spiking the potential interferent into drug free oral fluid containing oxycodone at $\pm 25\%$ of the cutoff. No interference was observed at the concentrations tested with structurally unrelated compounds. The concentration levels of structurally unrelated compounds tested was 40,000 ng/mL.
| Non-Interfering Structurally Unrelated Compounds |
| --- |
| 4-Bromo-2,5,Dimethoxyphenethylamine |
| Alprazolam |
| 7-Aminoclonazepam |
| 7-Aminoflunitrazepam |
| 7-Aminonitrazepam |
| Amitriptyline |
| S-(+) Amphetamine |
| Benzylpiperazine |
| Bromazepam |
| Bupropion |
K203564 - Page 10 of 18
{10}
K203564 - Page 11 of 18
| Non-Interfering Structurally Unrelated Compounds |
| --- |
| Butabarbital |
| Butalbital |
| Cannabidiol |
| Cannabinol |
| Carbamazepine |
| Carisoprodol |
| Chlordiazepoxide |
| Chlorpromazine |
| Clobazam |
| Clomipramine |
| Clonazepam |
| Clozapine |
| Cocaine |
| Cotinine |
| Cyclobenzaprine |
| Demoxepam |
| Desalkylflurazepam |
| Desipramine |
| Diazepam |
| Digoxin |
| Dehydronorketamine |
| Delta-9-THC |
| Diphenhydramine |
| Dextromethorphan |
| Doxepin |
| Ecgonine |
| Ecgonine Methyl Ester |
| EDDP |
| EMDP |
| 1R,2S(-)-Ephedrine |
| 1S,2R(+)-Ephedrine |
| Ethyl-β-D-Glucuronide |
| Fenfluramine |
| Flunitrazepam |
| Fluoxetine |
| Flurazepam |
| Haloperidol |
| 11-hydroxy-delta-9-THC |
| Imipramine |
| Ketamine |
{11}
K203564 - Page 12 of 18
| Non-Interfering Structurally Unrelated Compounds |
| --- |
| Lamotrigine |
| Lidocaine |
| Lorazepam |
| Lorazepam Glucuronide |
| Lormetazepam |
| LSD |
| Maprotiline |
| MDA |
| MDEA |
| MDMA |
| Meprobamate |
| S(+)-Methamphetamine |
| Methadone |
| Methaqualone |
| Methoxetamine |
| Methylone |
| Methylphenidate |
| Midazolam |
| N-desmethyltentadol |
| N-desmethyl tramadol |
| N-desmethyl venlafaxine |
| Nalorphine |
| Nitrazepam |
| 11-nor-9 carboxy THC |
| Nordiazepam |
| Norketamine |
| Norpropoxyphene |
| Norpseudoephedrine |
| Nortriptyline |
| O-desmethyl tramadol |
| O-desmethyl venlafaxine |
| Olanzapine |
| Oxazepam |
| Pentazocine |
| Pentobarbital |
| Phencyclidine |
| Phenobarbital |
| Phentermine |
| Phenylephrine |
| Phenytoin |
{12}
| Non-Interfering Structurally Unrelated Compounds |
| --- |
| Phenylpropanolamine |
| PMA |
| Prazepam |
| Propranolol |
| Propoxyphene |
| Protriptyline |
| R,R(-)-Pseudoephedrine |
| S,S(+)-Pseudoephedrine |
| Ritalinic Acid |
| Salicylic Acid |
| Secobarbital |
| Sertraline |
| Sufentanil |
| Temazepam |
| Theophylline |
| Thioridazine |
| Trazadone |
| Triazolam |
| Trifluoromethylphenyl-piperazine |
| Trimipramine |
| Venlafaxine |
| Verapamil |
| Zolpidem Tartrate |
## Interference – Endogenous Compounds and Exogenous Compounds
Endogenous compounds and exogenous compounds were evaluated in qualitative and semi-quantitative modes by spiking the potential interferent into drug free oral fluid containing oxycodone at $\pm 25\%$ of the cutoff. Additional orally used products were tested by collecting oral fluid using Quantisal and Quantisal II Oral Fluid Collection Devices from subjects after use of the substances. At the levels tested, there was no interference observed with endogenous compounds, exogenous compounds and orally used compounds. Endogenous compounds and exogenous compounds are presented in the first and second tables below. Orally used compounds are presented in the $3^{\mathrm{rd}}$ table below.
K203564 - Page 13 of 18
{13}
Non-interfering Endogenous Compounds
| Compound | Concentration Tested |
| --- | --- |
| Ascorbic Acid | 3 mg/mL |
| Bilirubin | 0.15 mg/mL |
| Cholesterol | 0.45 mg/mL |
| γ-Globulin | 0.8 mg/mL |
| Hemoglobin | 3 mg/mL |
| Human Serum Albumin | 15 mg/mL |
| IgA | 1 mg/mL |
| IgG | 1 mg/mL |
| IgM | 0.5 mg/mL |
| Salivary-α-amylase | 1000 U/mL |
Non-interfering Exogenous Compounds
| Compound | Concentration Tested |
| --- | --- |
| Acetaminophen | 0.1 mg/mL |
| Acetylsalicylic Acid | 0.1 mg/mL |
| Baking Soda | 0.6% v/v |
| Denture Adhesive | 0.6% w/v |
| Ibuprofen | 0.1 mg/mL |
| Alcohol (Ethanol) | 6% v/v |
| Caffeine | 0.1 mg/mL |
| Cough Syrup | 6% v/v |
| Coffee | 6% v/v |
| Cranberry Juice | 6% v/v |
| Hydrogen Peroxide (3% OTC) | 0.5% v/v |
| Milk | 1% v/v |
| Mouthwash | 6% v/v |
| Naproxen | 0.1 mg/mL |
| Orange Juice | 6% v/v |
| Soft Drink (Pepsi) | 6% v/v |
| Sodium Chloride | 18 mg/mL |
| Sugar | 50 mg/mL |
| Tea | 6% v/v |
| Toothpaste | 6% v/v |
K203564 - Page 14 of 18
{14}
Non-interfering Orally Used Exogenous Products
| Compound | Concentration Tested |
| --- | --- |
| Teeth Whitener | 2 strips |
| Cigarette | 1 cigarette |
| Hard Candy | 1 piece |
| Chewing Gum | 1 piece |
| Hydrogen Peroxide (3% OTC) | Neat (2 min. mouth rinse) |
| Sugar | 2 Teaspoons |
| Cough Syrup | 2 Teaspoons |
## Interference – pH
To evaluate potential interference from the effect of oral fluid pH, device performance in the qualitative and semi-quantitative modes was tested using a range of oral fluid pH values (3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0 and 11.0). All test samples were prepared in drug free oral fluid containing oxycodone at ±25% of the cutoff. At the pH levels tested, there was no interference observed for each test mode.
## 4. Assay Reportable Range:
The assay reportable range for the semi-quantitative mode is 10 ng/mL to 100 ng/mL.
## 5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):
### Traceability
The assay is traceable to a commercially available, certified, standard material with the concentration verified by GC-MS or LC-MS/MS.
### Oxycodone Stability in Oral Fluid
Drug free negative oral fluid spiked with oxycodone at +50% of the 30 ng/mL cutoff were collected and stored in Quantisal and Quantisal II Oral Fluid Collection Devices at 2°C - 8°C, tested by LC-MS/MS at each time point and compared to the baseline concentration result. The test results indicate that oral fluid samples containing oxycodone are stable for up to 12 months stored in Quantisal or Quantisal II Oral Fluid Collection Device at 2°C - 8°C.
Data to support 10-day storage in Quantisal or Quantisal II Oral Fluid Collection Device at ambient temperature 8°C - 25°C were reported in K183048 and K200801.
## 6. Detection Limit:
Not applicable
## 7. Assay Cut-Off:
The assay cut-off cutoff for the qualitative and semi-quantitative analysis of oxycodone in neat oral fluid is 30 ng/mL.
K203564 - Page 15 of 18
{15}
8. Carry-Over:
Not applicable
B Comparison Studies:
1. Method Comparison with Predicate Device:
Eighty (80) deidentified, unaltered clinical oral fluid samples collected using the Quantisal and Quantisal II Oral Fluid Collection Devices were obtained from clinical research facilities, analyzed for oxycodone at assay cutoff with the SEFRIA™ Oxycodone Oral Fluid Enzyme Immunoassay in both qualitative and semi-quantitative modes and compared to Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) results (using the Agilent 6430 Liquid Chromatography-Tandem Mass Spectrometry). Method comparison test results in qualitative and semi-quantitative modes are presented in the tables below.
Method Comparison –samples collected using Quantisal
| Immunoassay Result | LC-MS/MS Oxycodone Concentration | | | | Agreement (%) | |
| --- | --- | --- | --- | --- | --- | --- |
| | | < 15 ng/mL (less than-50% cutoff) | 15 – 29 ng/mL (between -50% cutoff and cutoff) | 30 – 45 ng/mL (between cutoff and +50% cutoff) | | > 45 ng/mL (greater than +50% cutoff) |
| Qual. | Positive | 0 | 0 | 5 | 35 | 100% (40/40) |
| | Negative | 36 | 4 | 0 | 0 | 100% (40/40) |
| Semi-Quant. | Positive | 0 | 0 | 5 | 35 | 100% (40/40) |
| | Negative | 36 | 4 | 0 | 0 | 100% (40/40) |
K203564 - Page 16 of 18
{16}
Method Comparison – samples collected using Quantisal II “Pad A”
| Immunoassay Result | LC-MS/MS Oxycodone Concentration | | | | Agreement (%) | |
| --- | --- | --- | --- | --- | --- | --- |
| | | < 15 ng/mL (less than -50% cutoff) | 15 – 29 ng/mL (between -50% cutoff and cutoff) | 30 – 45 ng/mL (between cutoff and +50% cutoff) | | > 45 ng/mL (greater than +50% cutoff) |
| Qual. | Positive | 0 | 0 | 5 | 35 | 100% (40/40) |
| | Negative | 36 | 4 | 0 | 0 | 100% (40/40) |
| Semi-Quant. | Positive | 0 | 0 | 5 | 35 | 100% (40/40) |
| | Negative | 36 | 4 | 0 | 0 | 100% (40/40) |
Method Comparison – samples collected using Quantisal II “Pad B”
| Immunoassay Result | LC-MS/MS Oxycodone Concentration | | | | Agreement (%) | |
| --- | --- | --- | --- | --- | --- | --- |
| | | < 15 ng/mL (less than -50% cutoff) | 15 – 29 ng/mL (between -50% cutoff and cutoff) | 30 – 45 ng/mL (between cutoff and +50% cutoff) | | > 45 ng/mL (greater than +50% cutoff) |
| Qual. | Positive | 0 | 0 | 5 | 35 | 100% (40/40) |
| | Negative | 36 | 4 | 0 | 0 | 100% (40/40) |
| Semi-Quant. | Positive | 0 | 0 | 5 | 35 | 100% (40/40) |
| | Negative | 36 | 4 | 0 | 0 | 100% (40/40) |
2. Matrix Comparison:
Not applicable. The assay is intended for use only with oral fluid samples.
C Clinical Studies:
1. Clinical Sensitivity:
Not applicable
K203564 - Page 17 of 18
{17}
2. Clinical Specificity:
Not applicable
3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):
Not applicable
D. Clinical Cut-Off:
Not applicable
E. Expected Values/Reference Range:
Not applicable.
VIII. Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
IX. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
K203564 - Page 18 of 18
